A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-Associated Pneumonia in Hospitalized Adults

Trial Profile

A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-Associated Pneumonia in Hospitalized Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Avibactam/ceftazidime (Primary) ; Meropenem
  • Indications Bacterial infections; Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms REPROVE; REPROVE-CAZ-AVI
  • Sponsors AstraZeneca; AstraZeneca AB
  • Most Recent Events

    • 25 Apr 2017 Results (n=2000) of subgroup analysis of this and other dataset assessing pharmacokinetic/pharmacodynamic validation presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 25 Apr 2017 Results assessing the safety and efficacy of ceftazidime-avibactam versus meropenem in adults with nosocomial pneumonia including ventilator-associated pneumonia, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 25 Apr 2017 Results of beta-lactamase characterization presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top